secwatch.observer — SEC 8-K summary
======================================

Issuer:     OnKure Therapeutics, Inc. (OKUR)
CIK:        0001637715
Form:       8-K
Filed at:   2022-02-02T23:59:59+00:00
Accession:  0001193125-22-025697
Event type: leadership
Sentiment:  negative
Materiality: 0.65
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Reneo Pharmaceuticals CFO Vineet R. Jindal resigns, effective March 31, 2022
----------------------------------------------------------------------------

- CFO Vineet R. Jindal notified resignation on Jan 28, 2022; effective March 31, 2022.
- Separation agreement includes 9 months base salary severance ($385k/year), 12 months COBRA.
- Equity vesting accelerated by 12 months; consulting engagement offered post-separation at $375/hour for 12 months.
- No replacement CFO named; Jindal to continue service until separation date.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1637715/000119312522025697/0001193125-22-025697-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1637715/000119312522025697/d304619d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-22-025697

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer